oral semaglutide results 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial Efficacy and safety of once-daily

Individuals who are overweight or obese (with a BMI of 25 or higher) or have one or more obesity-related conditions may be suitable candidates for GLP-1 therapy

In diabetic kidney disease rats treated with liraglutide, an increase in the Simpson diversity index was observed together with marked improvements in renal tubular structure, demonstrating that the renoprotective effect of liraglutide was linked to enhancements in gut microbiota composition

Stability: Long shelf-life under proper storage conditions

PMID: 25415472 Bajramagic S, Sever M, Rasic F, et al

Formononetin attenuates kidney damage in type 2 diabetic rats

Check out our full review of Bio Complete 3